The metastasis problem gets stickier.
The enormity and complexity of cancer genome data present significant challenges in downstream validation of novel oncogenes and tumor suppressors. In this issue of Cancer Cell, Hu et al. evaluate candidate oncogenes in a recurrent amplification in poor-prognosis breast cancers. They identify and validate the prometastatic gene metadherin (MTDH) as a key modulator of endothelial adhesion and chemoresistance.
Kwong
Lawrence N
LN
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Chin
Lynda
L
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009362:Neoplasm Metastasis / Q000235:genetics / Q000473:pathology; D011379:Prognosis
D015815:Cell Adhesion Molecules